Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.

ABSTRACT:

Background

The programmed death-1 (PD-1) inhibitor nivolumab prolongs disease-free survival in patients with muscle-invasive urothelial carcinoma (MIUC).

Objective

To evaluate the effects of nivolumab on health-related quality of life (HRQoL) after radical resection in patients with MIUC.

Design, setting, and participants

We used data from 709 patients in CheckMate 274 (NCT02632409; 282 with programmed death ligand 1 [PD-L1] expression ≥1%), an ongoing randomized, double-blind, placebo-controlled phase 3 trial of adjuvant nivolumab.

Intervention

Intravenous injection of nivolumab (240 mg) or placebo every 2 wk for ≤1 yr.

Outcome measurements and statistical analysis

HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Q

SUBMITTER: Witjes JA 

PROVIDER: S-EPMC10062393 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature